Presented by:
Raymond B. Mailhot, MD, MPH
Assistant Professor, University of Florida Department of Radiation Oncology,
UF Health Proton Therapy Institute
Faculty Disclosure:
Dr. Mailhot has disclosed that he has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/. All relevant financial relationships have been mitigated.
Release Date: October 18, 2021
Expiration Date: October 17, 2022
Target Audience: This course is intended for an audience of specialty physicians, primary care physicians, physician assistants, nurses, as well as others who treat patients with Hodgkin lymphoma.
Learning Objectives:
As a result of participation in this activity, participants should be able to:
- Discuss best practices of the use of radiation therapy for Hodgkin lymphoma based on current research.
- Define proton therapy and describe how proton therapy is different from conventional radiation therapy.
- Identify and determine the theoretical advantages to the use of proton therapy in the treatment of Hodgkin lymphoma.
Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.
Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Resource(s) for further study:
1) Hoppe BS, Mailhot Vega RB, Mendenhall NP, et al. Irradiating Residual Disease to 30 Gy with Proton Therapy in Pediatric Mediastinal Hodgkin Lymphoma. Int J Part Ther. 2020;6(4):11-16. doi:10.14338/IJPT-19-00077.1
2) Raymond B. Mailhot Vega & Bradford S. Hoppe (2020) A positive approach: advances in proton therapy for the treatment of mediastinal lymphoma, Expert Review of Hematology, 13:3, 197-200, DOI: 10.1080/17474086.2020.1713745
3) Hoppe BS, Bates JE, Mendenhall NP, et al. The Meaningless Meaning of Mean Heart Dose in Mediastinal Lymphoma in the Modern Radiation Therapy Era. Pract Radiat Oncol. 2020;10(3):e147-e154. doi:10.1016/j.prro.2019.09.015
If you have any questions please feel free to contact Christina Mershell at (904) 831-4034 or clmershell@floridaproton.org.